Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment
Protein-protein interactions (PPIs) form complex cellular networks fundamental to many key biological processes, including signal transduction, cell proliferation and DNA repair. In consequence, their perturbation is often associated with many human diseases. Targeting PPIs offers a promising approa...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Pharmacological Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661824004894 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553861020483584 |
|---|---|
| author | Cristina Camps-Fajol Debora Cavero Jordi Minguillón Jordi Surrallés |
| author_facet | Cristina Camps-Fajol Debora Cavero Jordi Minguillón Jordi Surrallés |
| author_sort | Cristina Camps-Fajol |
| collection | DOAJ |
| description | Protein-protein interactions (PPIs) form complex cellular networks fundamental to many key biological processes, including signal transduction, cell proliferation and DNA repair. In consequence, their perturbation is often associated with many human diseases. Targeting PPIs offers a promising approach in drug discovery and ongoing advancements in this field hold the potential to provide highly specific therapies for a wide range of complex diseases. Despite the development of PPI modulators is challenging, advances in the genetic, proteomic and computational level have facilitated their discovery and optimization. Focusing on anticancer drugs, in the last years several PPI modulators have entered clinical trials and venetoclax, which targets Bcl-2 family proteins, has been approved for treating different types of leukemia. This review discusses the clinical development status of drugs modulating several PPIs, such as MDM2–4/p53, Hsp90/Hsp90, Hsp90/CDC37, c-Myc/Max, KRAS/SOS1, CCR5/CCL5, CCR2/CCL2 or Smac/XIAP, in cancer drug discovery. |
| format | Article |
| id | doaj-art-f98a72aa3ac04e7aaa3c2eead3896a5f |
| institution | Kabale University |
| issn | 1096-1186 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pharmacological Research |
| spelling | doaj-art-f98a72aa3ac04e7aaa3c2eead3896a5f2025-01-09T06:13:03ZengElsevierPharmacological Research1096-11862025-01-01211107544Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatmentCristina Camps-Fajol0Debora Cavero1Jordi Minguillón2Jordi Surrallés3Unitat Mixta de Recerca en Medicina Genòmica, Universitat Autònoma de Barcelona (UAB)-IR SANT PAU, Barcelona, Spain; Institut de Bioenginyeria de Catalunya (IBEC), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CIBERER, ISCIII), Madrid, SpainUnitat Mixta de Recerca en Medicina Genòmica, Universitat Autònoma de Barcelona (UAB)-IR SANT PAU, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CIBERER, ISCIII), Madrid, SpainCIBERER-ISCIII, IdiPAZ-CNIO Translational Research Unit in Pediatric Hemato-Oncology, La Paz University Hospital Research Institute; Spanish National Cancer Center, Madrid, Spain; Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, SpainUnitat Mixta de Recerca en Medicina Genòmica, Universitat Autònoma de Barcelona (UAB)-IR SANT PAU, Barcelona, Spain; Institut de Bioenginyeria de Catalunya (IBEC), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III (CIBERER, ISCIII), Madrid, Spain; Servei de Genètica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Spain; Correspondence to: Joint Research Unit on Genomic Medicine, Universitat Autònoma de Barcelona (UAB)-IR SANT PAU. DNA repair and Cancer Predisposition Syndromes Group, Carrer de Sant Quintí, 77, Barcelona 08041, Spain.Protein-protein interactions (PPIs) form complex cellular networks fundamental to many key biological processes, including signal transduction, cell proliferation and DNA repair. In consequence, their perturbation is often associated with many human diseases. Targeting PPIs offers a promising approach in drug discovery and ongoing advancements in this field hold the potential to provide highly specific therapies for a wide range of complex diseases. Despite the development of PPI modulators is challenging, advances in the genetic, proteomic and computational level have facilitated their discovery and optimization. Focusing on anticancer drugs, in the last years several PPI modulators have entered clinical trials and venetoclax, which targets Bcl-2 family proteins, has been approved for treating different types of leukemia. This review discusses the clinical development status of drugs modulating several PPIs, such as MDM2–4/p53, Hsp90/Hsp90, Hsp90/CDC37, c-Myc/Max, KRAS/SOS1, CCR5/CCL5, CCR2/CCL2 or Smac/XIAP, in cancer drug discovery.http://www.sciencedirect.com/science/article/pii/S1043661824004894Protein-protein interactionPPIModulatorsApprovedClinical trialsCancer treatment |
| spellingShingle | Cristina Camps-Fajol Debora Cavero Jordi Minguillón Jordi Surrallés Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment Pharmacological Research Protein-protein interaction PPI Modulators Approved Clinical trials Cancer treatment |
| title | Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment |
| title_full | Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment |
| title_fullStr | Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment |
| title_full_unstemmed | Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment |
| title_short | Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment |
| title_sort | targeting protein protein interactions in drug discovery modulators approved or in clinical trials for cancer treatment |
| topic | Protein-protein interaction PPI Modulators Approved Clinical trials Cancer treatment |
| url | http://www.sciencedirect.com/science/article/pii/S1043661824004894 |
| work_keys_str_mv | AT cristinacampsfajol targetingproteinproteininteractionsindrugdiscoverymodulatorsapprovedorinclinicaltrialsforcancertreatment AT deboracavero targetingproteinproteininteractionsindrugdiscoverymodulatorsapprovedorinclinicaltrialsforcancertreatment AT jordiminguillon targetingproteinproteininteractionsindrugdiscoverymodulatorsapprovedorinclinicaltrialsforcancertreatment AT jordisurralles targetingproteinproteininteractionsindrugdiscoverymodulatorsapprovedorinclinicaltrialsforcancertreatment |